| 生物活性 |
Cucurbitacin IIa (Hemslecin A) is an orally active, blood-brain barrier-penetrant EGFR inhibitor with an IC50 of 1.455 nM against human EGFR that exerts anti-inflammatory activity by inducing caspase-3-dependent apoptosis, downregulating survivin expression, enhancing autophagy, disrupting the actin cytoskeleton via actin aggregation, arresting the cell cycle at the G2/M phase, and inhibiting the EGFR-MAPK signaling pathway, and can be used for research on inflammation-related diseases, depression, and cancers such as non-small cell lung cancer. |
体外研究 (In Vitro) |
Cucurbitacin IIa (0.1-1000 μM;24-48 h) 可剂量依赖性地抑制 RAW 264.7 巨噬细胞的增殖,其 IC50 值在 24 h 时为 122.32 μM,在 48 h 时为 6.42 μM。 Cucurbitacin IIa (2.5-40 μM;24 h) 可剂量依赖性地抑制 RAW 264.7 巨噬细胞的迁移。 Cucurbitacin IIa (2.5-40 μM;5 h) 不会抑制 RAW 264.7 巨噬细胞中 LPS (MS-X54539) 诱导的 TNF-α 表达。 Cucurbitacin IIa (2.5-40 μM;5 h) 在 RAW 264.7 巨噬细胞中不会抑制 LPS 诱导的 MAPK(p38、ERK1/2、JNK) 磷酸化,也不会抑制 NF-κB 通路组分 (IκBα、p65) 的磷酸化。 Cucurbitacin IIa (2.5-40 μM;6-24 h) 可在经 LPS 刺激 (而非未刺激) 的 RAW 264.7 巨噬细胞中诱导依赖 caspase-3 的细胞凋亡,亚 G0/G1 期细胞群增加、活化型 caspase-3 水平升高及 survivin 表达降低可证明这一点。 Cucurbitacin IIa (2.5-40 μM;6-24 h) 可呈剂量依赖性增强 LPS 诱导的 RAW 264.7 巨噬细胞自噬,这一点可通过 LC3B-II 水平升高及 LC3 斑点形成增强得到证实。 Cucurbitacin IIa 通过诱导肌动蛋白聚集破坏 RAW 264.7 巨噬细胞的肌动蛋白细胞骨架,处理后细胞中 G-actin/F-actin 比值的改变和肌动蛋白的异常分布可证明这一点。 Cucurbitacin IIa (0.1-100 μg/mL;48 h) 可降低人前列腺癌细胞 CWR22Rv-1、PC-3 以及人肺癌细胞 NCI-H1299 的活力并抑制其生长。 Cucurbitacin IIa (10 μg/mL;2 h) 可使转染 EGFP-actin 的小鼠 NIH 3T3 细胞中的丝状肌动蛋白发生不可逆聚集。 Cucurbitacin IIa (50 μg/mL;48 h) 可破坏人前列腺癌 CWR22Rv-1 细胞中的肌动蛋白细胞骨架,但不会影响其微管细胞骨架。 Cucurbitacin IIa (10 μg/mL;16 h) 可诱导亲本型人前列腺癌 CWR22Rv-1 细胞发生 G2/M 期细胞周期阻滞,并提升亚 G1 期 (凋亡) 细胞群占比;而在过表达 δ-catenin 的 CWR22Rv-1 细胞中,上述作用受到抑制。 Cucurbitacin IIa (1-50 μg/mL;16 h) 可降低人前列腺癌 CWR22Rv-1 和 PC-3 细胞、人肺癌 NCI-H1299 细胞中磷酸化组蛋白 H3 和 survivin 的表达水平,提高剪切型 PARP 的水平,并降低 RhoA 的丝氨酸 188 磷酸化水平,且不会抑制 JAK2/STAT3 的磷酸化。 Cucurbitacin IIa (5-40 μg/mL;72 h) 可诱导人前列腺癌 PC-3 和 CWR22Rv-1 细胞发生凋亡性 DNA 片段化。 Cucurbitacin IIa (1-50 μg/mL;16 h) 可降低人前列腺癌 CWR22Rv-1 细胞中 RhoA 的丝氨酸 188 位磷酸化水平。 Cucurbitacin IIa (50 μg/mL;48 h) 可诱导 F-actin 聚集,但不会改变人肺癌 NCI-H1299 细胞中 STAT3 的亚细胞定位。 Cucurbitacin IIa (40-80 μM;36 h) 可强效抑制 A549 细胞增殖,处理 36 h 后的 IC50 为 60 μM。 Cucurbitacin IIa (50-70 μM;36 h) 处理 A549 细胞 36 h 后,可诱导细胞呈剂量依赖性凋亡。 Cucurbitacin IIa (50-70 μM;36 h) 处理 A549 细胞 36 h 后可诱导其发生 G2/M 期细胞周期阻滞。 Cucurbitacin IIa (60 μM;1-5 h) 在 A549 细胞中改变 EGFR-MAPK 通路以及凋亡/细胞周期相关基因的转录水平;在所有时间点均存在 Raf1 和 STAT3 的显著上调,以及 MEK1 和 ERK1 的显著下调。 Cucurbitacin IIa (60 μM;1-24 h) 调控 A549 细胞中 EGFR-MAPK 通路相关蛋白、凋亡相关蛋白及细胞周期相关蛋白的积累与磷酸化,包括 survivin 的持续降解、磷酸化 MEK1/2 的持续减少以及磷酸化 BRAF 的持续升高。
Cell Migration Assay
| Cell Line: |
mouse RAW 264.7 macrophage cells |
| Concentration: |
2.5, 10, 40 μM |
| Incubation Time: |
24 h |
| Result: |
Markedly inhibited RAW 264.7 cell migration in a dose-dependent manner. Reduced migrated cell numbers significantly at all tested concentrations compared to control. |
Western Blot Analysis
| Cell Line: |
LPS-stimulated mouse RAW 264.7 macrophage cells |
| Concentration: |
2.5, 10, 40 μM |
| Incubation Time: |
1 h pretreatment, followed by 1 h LPS stimulation (MAPK analysis); 1 h pretreatment, followed by 4 h LPS stimulation (NF-κB analysis) |
| Result: |
Did not suppress LPS-induced phosphorylation of p38, ERK1/2, JNK, IκBα, or p65. Slightly increased MAPK phosphorylation levels at high doses. |
Apoptosis Analysis
| Cell Line: |
LPS-stimulated mouse RAW 264.7 macrophage cells |
| Concentration: |
2.5, 10, 40 μM |
| Incubation Time: |
6 h (WB); 24 h (morphological observation, flow cytometry, WB) |
| Result: |
Reduced the arborized morphology of LPS-activated cells and induced cell fragmentation. Elevated sub-G0/G1 apoptotic cell populations in LPS-stimulated cells to 17.55% (2.5 μM), 24.64% (10 μM), and 33.28% (40 μM), with no increase in apoptotic cells observed with treatment alone. Significantly increased cleaved caspase-3 levels in LPS-stimulated cells, with higher levels at 24 h than 6 h. Decreased survivin expression significantly in LPS-stimulated cells treated with 2.5 and 10 μM at 24 h. |
Cell Autophagy Assay
| Cell Line: |
LPS-stimulated mouse RAW 264.7 macrophage cells |
| Concentration: |
2.5, 10, 40 μM |
| Incubation Time: |
6 h, 24 h (western blot); 24 h (immunofluorescence microscopy, chloroquine combined treatment) |
| Result: |
Dose-dependently enhanced LPS-induced increases in LC3B-II levels, with greater effects at 24 h than 6 h. Further increased LC3B-II levels in LPS + Cucurbitacin IIa-treated cells when combined with chloroquine, confirming enhanced autophagic flux. Increased LC3B-II levels alone, but this effect was significantly lower than the LPS + Cucurbitacin IIa treatment at 24 h. Induced more LC3 puncta in LPS + Cucurbitacin IIa-treated cells than LPS alone-treated cells. |
Immunofluorescence
| Cell Line: |
human prostate cancer CWR22Rv-1 cells |
| Concentration: |
50 μg/mL |
| Incubation Time: |
48 h |
| Result: |
Caused severe clustering of F-actin. Showed no significant changes in microtubule structure compared to untreated cells. |
Cell Cycle Analysis
| Cell Line: |
human prostate cancer CWR22Rv-1 cells (parental and δ-catenin-overexpressing) |
| Concentration: |
10 μg/mL |
| Incubation Time: |
16 h |
| Result: |
Caused a 46% reduction in G1 phase, a decrease in S phase to 20%, a 5.5-fold increase in G2/M phase, and a 2.7-fold increase in sub-G1 phase in parental CWR22Rv-1 cells. Caused only a moderate decrease in S phase and a slight increase in G2/M phase, with no significant changes in G1 or sub-G1 phases in δ-catenin-overexpressing CWR22Rv-1 cells. |
Western Blot Analysis
| Cell Line: |
human prostate cancer CWR22Rv-1 and PC-3 cells, human lung cancer NCI-H1299 cells |
| Concentration: |
1, 50 μg/mL |
| Incubation Time: |
16 h |
| Result: |
Reduced levels of phospho-Histone H3 and survivin, and increased levels of cleaved PARP in all three cell lines. Reduced serine 188 phosphorylation of RhoA but did not alter total RhoA levels, total or phosphorylated STAT3, total or phosphorylated JAK2, or total or phosphorylated ERK1/2 in CWR22Rv-1 cells. Had no significant effect on total or phosphorylated STAT3 or JAK2, and only marginally reduced JAK2 phosphorylation in NCI-H1299 cells. |
Apoptosis Analysis
| Cell Line: |
human prostate cancer PC-3 and CWR22Rv-1 cells |
| Concentration: |
5, 40 μg/mL |
| Incubation Time: |
72 h |
| Result: |
Induced clear DNA fragmentation, a hallmark of apoptosis, in both cell lines. |
Immunofluorescence
| Cell Line: |
human prostate cancer CWR22Rv-1 cells |
| Concentration: |
1, 50 μg/mL |
| Incubation Time: |
16 h |
| Result: |
Significantly reduced RhoA phosphorylation at serine 188, with a more pronounced reduction observed at 50 μg ml⁻1 compared to 1 μg ml⁻1. |
Immunofluorescence
| Cell Line: |
human lung cancer NCI-H1299 cells |
| Concentration: |
50 μg/mL |
| Incubation Time: |
48 h |
| Result: |
Induced F-actin clustering but did not alter the mixed nuclear and cytoplasmic distribution of STAT3 compared to untreated cells. |
Cell Viability Assay
| Cell Line: |
A549 |
| Concentration: |
40, 50, 60, 70, 80 μM |
| Incubation Time: |
36 h |
| Result: |
Inhibited A549 cell proliferation in a dose-dependent manner, with an IC50 v...(内容过长已截断) |
体内研究 (In Vivo) |
Cucurbitacin IIa (30-90 mg/kg;腹腔注射、灌胃、静脉注射;每日 1 次;连续 10 天) 可剂量依赖性地抑制 C57 小鼠体内 H22 肝癌的肿瘤生长。 Cucurbitacin IIa 呈剂量依赖性抑制 C57 小鼠体内 Lewis 肺癌的肿瘤生长。 Cucurbitacin IIa (2.5-5 mg/kg;腹腔注射;每日 1 次;持续 5 周) 在慢性不可预测温和应激 (CUMS) 暴露小鼠中呈现剂量依赖性的类抗抑郁作用。
| Animal Model: |
C57 mice |
| Dosage: |
30-90 mg/kg (i.p.); 30-90 mg/kg (p.o.); 5-15 mg/kg (i.v.) |
| Administration: |
i.p.; daily; 10 days; p.o.; daily; 10 days; i.v.; daily; 10 days |
| Result: |
Reduced mean tumour weight. |
| Animal Model: |
BALB/c (adult male, 18-22 g, chronic unpredictable mild stress-induced) |
| Dosage: |
2.5 mg/kg; 5 mg/kg (CUMS mice); 5 mg/kg (naive mice) |
| Administration: |
i.p.; daily; 5 weeks (1 hour before CUMS procedures/behavioral tests); i.p. (naive mice) |
| Result: |
Restored the behavioral indicators, synaptic receptor expression levels, and levels of CaMKII-CREB-BDNF pathway markers in mice to normal states.
|
|
| 性状 |
固体 |
| 颜色 |
White to off-white |
| 分子量 |
562.73 |
| 分子式 |
C32H50O8 |
| CAS No. |
58546-34-2 |
| 别名 |
雪胆素A; Hemslecin A |
| 体内实验配方 |
10% DMSO+90% Saline: < 10 mg/mL (17.77 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. ![]() 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (17.77 mM), Solution. ![]() 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 |
| 储存方式 |
4°C, protect from light
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere. |
|
溶液配制表
|
DMSO 中的溶解度 : 25 mg/mL (44.43 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO) | 可选溶剂 | 浓度 | 1 mg | 5 mg | 10 mg | 25 mg |
|---|
| DMSO | 1 mM | 1.7771 mL | 8.8853 mL | 17.7705 mL | 44.4263 mL | | 5 mM | 0.3554 mL | 1.7771 mL | 3.5541 mL | 8.8853 mL | | 10 mM | 0.1777 mL | 0.8885 mL | 1.7771 mL | 4.4426 mL | | 15 mM | 0.1185 mL | 0.5924 mL | 1.1847 mL | 2.9618 mL | | 20 mM | 0.0889 mL | 0.4443 mL | 0.8885 mL | 2.2213 mL | | 25 mM | 0.0711 mL | 0.3554 mL | 0.7108 mL | 1.7771 mL | | 30 mM | 0.0592 mL | 0.2962 mL | 0.5924 mL | 1.4809 mL | | 40 mM | 0.0444 mL | 0.2221 mL | 0.4443 mL | 1.1107 mL |
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。
|
动物实验计算换算器
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。
-
客服
2851296953
18923798467
微信洽谈
|